KORU Medical Systems (KRMD) Expected to Announce Earnings on Thursday

KORU Medical Systems (NASDAQ:KRMD) will likely be posting its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.90 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

KORU Medical Systems Price Performance

Shares of NASDAQ:KRMD opened at $4.85 on Thursday. KORU Medical Systems has a 12 month low of $1.86 and a 12 month high of $6.61. The firm has a market capitalization of $224.65 million, a P/E ratio of -60.63 and a beta of 0.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92. The company’s fifty day moving average price is $5.31 and its 200 day moving average price is $4.78.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of KRMD. Invesco Ltd. raised its stake in shares of KORU Medical Systems by 24.8% during the fourth quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock worth $162,000 after purchasing an additional 5,546 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new position in KORU Medical Systems in the 4th quarter valued at $127,000. Price T Rowe Associates Inc. MD increased its stake in KORU Medical Systems by 26.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock valued at $158,000 after buying an additional 5,649 shares during the period. Russell Investments Group Ltd. raised its position in KORU Medical Systems by 28.3% during the 4th quarter. Russell Investments Group Ltd. now owns 195,773 shares of the company’s stock worth $1,137,000 after buying an additional 43,215 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of KORU Medical Systems by 8,719.9% in the 4th quarter. Royal Bank of Canada now owns 133,004 shares of the company’s stock worth $773,000 after acquiring an additional 131,496 shares during the period. Institutional investors and hedge funds own 58.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on KRMD. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Canaccord Genuity Group raised their price target on KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Wall Street Zen upgraded KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 12th. Lake Street Capital increased their price objective on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $7.00 target price on shares of KORU Medical Systems in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $6.13.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.